Evidence map›Paper›PMID 37722485›Full record

ArticleContemporary clinical trials2023

Brief cognitive-behavioral treatment for avoidant/restrictive food intake disorder in the context of functional dyspepsia: Study protocol for a feasibility randomized controlled trial.

Helen Burton Murray, Brjánn Ljótsson, Brian Healy, Lukas Van Oudenhove, Jonathan S Williams, Laurie Keefer, Elizabeth A Lawson, Braden Kuo, Jennifer J Thomas

Open access · greenAbstract readClinical Trial Protocol
In one paragraph

Article in Contemporary clinical trials, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 3 countries.

Helen Burton MurrayHarvard Medical School, Boston, MA, USA; Multidisciplinary Eating Disorders Research Collaborative, Mass General Brigham, Boston, MA, USA; Division of Gastroenterology, Massachusetts General Hospital, Boston, MA, USA. Electronic address: hbmurray@mgh.harvard.edu.
Brjánn LjótssonDepartment of Clinical Neuroscience, Division of Psychology, Karolinska Institutet, Stockholm, Sweden.
Brian HealyHarvard Medical School, Boston, MA, USA; Biostatistics Center, Massachusetts General Hospital, Boston, MA, USA.
Lukas Van OudenhoveLaboratory for Brain-Gut Axis Studies (LaBGAS), Translational Research in Gastrointestinal Disorders (TARGID), Department of Chronic Diseases and Metabolism (CHROMETA), KU Leuven, Leuven, Belgium; Leuven Brain Institute, KU Leuven, Leuven, Belgium; Cognitive and Affective Neuroscience Lab, Department of Psychological and Brain Sciences, Dartmouth College, Hanover, NH, USA.
Jonathan S WilliamsHarvard Medical School, Boston, MA, USA; Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Boston, MA, USA.
Laurie KeeferIcahn School of Medicine at Mount Sinai, NY, New York, USA.
Elizabeth A LawsonHarvard Medical School, Boston, MA, USA; Multidisciplinary Eating Disorders Research Collaborative, Mass General Brigham, Boston, MA, USA; Neuroendocrine Unit, Massachusetts General Hospital, Boston, MA, USA.
Braden KuoHarvard Medical School, Boston, MA, USA; Division of Gastroenterology, Massachusetts General Hospital, Boston, MA, USA.
Jennifer J ThomasHarvard Medical School, Boston, MA, USA; Multidisciplinary Eating Disorders Research Collaborative, Mass General Brigham, Boston, MA, USA; Eating Disorders Clinical and Research Program, Massachusetts General Hospital, Boston, MA, USA.
Harvard University · USBrigham and Women's Hospital · USDartmouth College · USIcahn School of Medicine at Mount Sinai · USKarolinska Institutet · SE

Funding

New England Gastropareis Consortium: Neurobiology of GastroparesisU01DK112193 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI Helen Burton Murray, Braden Kuo · 2016 to 2026
$4.8M
Neurobiological Underpinnings of Avoidant/Restrictive Food Intake Disorder in AdultsR01MH128246 · NIMH · MASSACHUSETTS GENERAL HOSPITAL · PI LAURA McGrath HOLSEN, Elizabeth Austen Lawson · 2022 to 2026
$4.5M
TRANSLUMBOSACRAL NEUROMODULATION THERAPY FOR FECAL INCONTINENCE: RANDOMIZED TRIALR01DK121003 · NIDDK · AUGUSTA UNIVERSITY · PI KUO, BRADEN, RAO, SATISH SC · 2019 to 2023
$2.6M
A Biobehavioral Approach to Understand Problematic Avoidant/Restrictive Eating in Adults with Functional DyspepsiaK23DK131334 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI BURTON MURRAY, HELEN · 2021 to 2025
$1.1M
Neurobiology of avoidant/restrictive eating in youthK24MH120568 · NIMH · MASSACHUSETTS GENERAL HOSPITAL · PI LAWSON, ELIZABETH AUSTEN · 2019 to 2023
$961k
NIDDK NIH HHS K23 DK131334NIDDK NIH HHS R01 DK121003NIDDK NIH HHS U01 DK112193NIMH NIH HHS K24 MH120568NIMH NIH HHS R01 MH128246
6 · The paper itself

Abstract

backgroundAvoidant/restrictive food intake disorder (ARFID) symptoms are common (up to 40%) among adults with functional dyspepsia (FD), a disorder of gut-brain interaction characterized by early satiation, post-prandial fullness, epigastric pain, and/or epigastric burning. Using an 8-session exposure-based cognitive-behavioral treatment (CBT) for adults with FD + ARFID compared to usual care (UC) alone, we aim to: (1) determine feasibility, (2) evaluate change in clinical outcomes in, and (3) explore possible mechanisms of action.

methodsWe will randomize adults with FD who meet criteria for ARFID with ≥5% weight loss (N = 50) in a 1:1 ratio to CBT (with continued UC) or to UC alone. A priori primary benchmarks will be: ≥75% eligible participants enroll; ≥75% participants complete assessments; ≥70% participants attend 6/8 sessions; ≥70% of sessions have all content delivered; ≥70% participants rate Client Satisfaction Questionnaire scores above scale midpoint. We will also examine the size of changes in FD symptom severity and related quality of life within and between groups, and explore possible mechanisms of action.

conclusionsFindings from this trial will inform next steps with treatment development or evaluation-either for further refinement or for next-step efficacy testing with a fully-powered clinical trial.

Indexed as

Avoidant Restrictive Food Intake DisorderDyspepsiaFeeding and Eating DisordersAdultCognitionEatingFeasibility StudiesHumansQuality of LifeRandomized Controlled Trials as TopicRetrospective StudiesAvoidant/restrictive food intake disorderCognitive-behavioral therapyDisorders of gut-brain interactionFeasibilityFeeding and eating disordersFunctional dyspepsia

Identifiers

PMID37722485
PMCPMC11232673
OpenAlexW4386799975

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.